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Introduction
Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder characterized by reduced levels of α-1 antitrypsin, also known as α-1 proteinase inhibitor (A 1 -PI) [1] . A 1 -PI has a central role in maintaining lung tissue integrity by preventing the degradation of lung tissue that occurs following exposure to elevated levels of uninhibited neutrophil elastase. The resultant lung density decline eventually progresses to clinically evident emphysema [2] .
Currently, the only treatment available that targets the underlying cause of AATD is infusion with purified human A 1 -PI. The use of A 1 -PI therapy has been accompanied by the assumption that increasing serum levels of A 1 -PI would increase neutrophil elastase inhibition and help to arrest lung tissue deterioration [2] . Serum concentrations of A 1 -PI >11 μmol l -1 have been suggested as a protective threshold against lung damage/emphysema [2] . This level is equivalent to the 10 th percentile of the A 1 -PI range of individuals with the moderately deficient PI*SZ genotype -who express a minimal increased risk of developing lung disease as compared with normal humans (PI*MM) -and is considered to be sufficient to prevent lung tissue damage [3] . However, this putative protective threshold is controversial; it was based on historical epidemiological data and the estimation made use of nonvalidated standards [4] . Despite the limitations of this threshold, it remains an important clinical criterion in the decision to prescribe A 1 -PI therapy [4, 5] .
In the Randomized, placebo-controlled trial of augmentation therapy in Alpha-1 Proteinase Inhibitor Deficiency (RAPID-RCT) study, A 1 year -1 [95% CI 0.06-1.42], P = 0.03 [6] . Data from the 2-year open-label RAPID-OLE trial indicated that patients who switched from placebo to A 1 -PI subsequently benefitted from a statistically significant reduction (difference 0.52 g l -1 year -1 [95% CI 0.22-0.83], P = 0.001) in the rate of lung density decline. However, these patients never caught up with those who had started active treatment in RAPID-RCT, owing to irreversible destruction of the lung tissue [7] . To further evaluate the treatment effect of A 1 -PI therapy in the RAPID programme, and characterize potential sources of variability, we report post hoc pharmacometric modelling of the combined RAPID-RCT and RAPID-OLE data. Two analyses were conducted using a sequential modelling approach. The objective of the initial dose-exposure analysis was to characterize the relationship between A 1 -PI dose and post-baseline A 1 -PI serum levels (exposure). In addition, we also sought to characterize potential sources of variability in A 1 -PI concentrations, both in placebo-treated and A 1 -PI-treated patients. The second analysis was an exposure-response analysis; using lung density at total lung capacity (TLC) as the measure of clinical response, we sought to evaluate the extent to which A 1 -PI exposure relates to clinical response. In addition, the clinical efficacy of the 60 mg kg -1 week -1 dosing strategy, and potential sources of variability in lung density decline rate, were evaluated.
Methods
This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki (version of 1996), the US Code of Federal Regulations, and local legal requirements. CSL Behring and the investigators informed each other in writing that all ethical and legal requirements were met before the first subject was enrolled in the study. . The RAPID-OLE trial was a 2-year open-label continuation of RAPID-RCT in 140 patients in sites outside of the USA as A 1 -PI was unavailable in non-USA countries. Patients who previously received A 1 -PI in RAPID-RCT continued their weekly infusions in the RAPID-OLE trial and formed the Early-Start group (A 1 -PI-A 1 -PI; n = 76); those patients who received placebo in RAPID-RCT were switched to A 1 -PI in RAPID-OLE and are referred to as the Delayed-Start group (Placebo-A 1 -PI; n = 64). Samples for serum A 1 -PI measurement were collected every 3 months at trough (defined as 7 days after last infusion) throughout the full 4-year RAPID programme; CT lung scans were performed at baseline and 3, 12, 21, 24, 36 and 48 months post-randomization. Baseline demographics at the beginning of the RAPID-RCT study are shown in Table 1 . Demographics were similar between A 1 -PI and placebo groups and between RAPID-RCT and RAPID-OLE [6, 7] . Additionally, withdrawal rates were comparable between study cohorts; primary results from the RAPID programme have previously been published [6, 7] .
Data sets
The dose-exposure analysis contained all randomized patients with at least one postbaseline A 1 -PI measurement. From the RAPID-RCT cohort, baseline A 1 -PI data were available from 170 patients (89 active; 81 placebo); from RAPID-OLE, data were available from 138 patients (74 EarlyStart; 64 Delayed-Start). The exposure-response analysis included all subjects in the dose-exposure model who had at least one postbaseline CT lung density measurement; data were available from 61 placebo and 73 active patients. For each subject, an average dose rate, expressed in mg day -1 (i.e., not standardized with respect to weight) and a median nominal trough exposure, expressed as μmol l -1 , were computed for each of the trials (RAPID-RCT and open-label RAPID-OLE). In some cases, nominal trough values may not have reflected true troughs, e.g., due to errant values derived from serum samples collected outside ± 1 day of the sampling time points stipulated in the study protocol. To protect against the influence of nontrough samples, exposure profiles over time (within each trial) were summarized using median rather than mean values.
Software
All data assembly and data analyses (including exploratory data analysis, modelling and simulation) were carried out using version 3.2.3 of R [8] . All models were fit using the nlme function in the nlme package for R, version 3.1-125.
Modelling strategy
Two analyses were conducted using a sequential modelling approach: (i) dose-exposure analysis, and (ii) exposureresponse analysis. The modelling strategy is described as dose-exposure rather than a pharmacokinetic analysis as only summary exposure measures were modelled. Covariates tested in the models were included due to mechanistic plausibility and clinical interest (see Supporting Information). All models were based on a single dose strength of A 1 -PI, i.e., 60 mg kg -1 week -1 , as used in the RAPID-RCT and RAPID-OLE trials.
Dose-exposure model
Exposure data for placebo-treated patients were available from RAPID-RCT only. In order to compare A 1 -PI and placebo for the combined duration of the RAPID-RCT and RAPID-OLE trials, RAPID-RCT was used as a starting point and extended with a random effect, accounting for the repeated measures structure of the data. The average dose rate (D) and the median exposure levels (C) for patient i, in the two phases of the RAPID programme (i.e., RAPID-RCT and RAPID-OLE) are denoted D i1 & D i2 and C i1 & C i2 , respectively. The base model is represented by equation (1), with j denoting study phase:
If this regression model were to be used in the context of a nonbiological agent with linear pharmacokinetics, the slope of steady-state concentration with respect to dose rate would be interpretable as the reciprocal of clearance. Such a parameter interpretation is only approximately correct for an endogenous compound with non-negligible baseline levels, and the model must therefore be understood as a linear empirical characterization of the relationship. With regard to distributional assumptions, both the random effects η 1 , i and the residual errors ϵ ij are assumed to be normally (independently and identically) distributed for all i.
The base model was extended to incorporate covariates. Observed (pre-treatment) baseline A 1 -PI exposure was naturally assumed to be predictive of on-treatment A 1 -PI levels and so was included in the model as a pre-set covariate, multiplying the intercept by the expression
where C base i
is the observed baseline A 1 -PI and the denominator, 5.5, equates approximately to the median pre-treatment A 1 -PI concentration among those who were randomized to Table 1 Baseline demographics in RAPID-RCT (ITT population) [6] 
Exposure-response model
The exposure-response model was developed to relate A 1 -PI exposure during RAPID-RCT/RAPID-OLE to a physiological endpoint, i.e., lung density determined by CT at TLC. In the combined duration of RAPID-RCT and RAPID-OLE, each patient had seven scheduled lung density assessments -five within the first 2 years, with annual scans over the last 2 years. Based on graphical exploration of individual longitudinal profiles for TLC lung density vs. study day (see randomly selected individual profiles in Figure S1 ), a base model that was piecewise linear in time was selected:
Here, Y denotes lung density at TLC; the subscript i again indexes patients, subscript j indexes study phase (j = 1 or 2 to indicate RAPID-RCT or RAPID-OLE, respectively), and now subscript k indexes assessment times. Time t ijk is expressed in days since randomization of patient i in the RAPID-RCT study. The expressions minimum(720, t ijk ) and maximum(0, t ijk -720) allow for a slope transition from DP i1 to DP i2 at t ijk = 720 days, when the Extension study begins (this is the piecewise linearity assumption). The term ϵ ijk reflects residual error, assumed to be normally distributed. The base model incorporates submodels used for the intercepts and diseaseprogression rates as follows:
All four η terms indicate patient-specific random effects, all of which were assumed to be multivariate normal (with zero mean vector). For example, the expression θ 1 + η 1 , i represents patient-specific baseline disease severity for patient i. The asterisks in the terms C Ã i1 and C Ã i2 indicate that exposure levels were centred at the median placebo levels observed in RAPID-RCT. This facilitates the interpretation of model parameters, such that θ 2 + η 2 , i represents the patient-specific progression rate for patient i during RAPID-RCT that would have been observed in the absence of treatment, i.e., the natural rate of lung density decline for this patient. Note that since the progression rates DP i1 and DP i2 share the common expression
À , the intertrial difference in progression rate for patient i is formalized by the expression (θ 4 + η 4,i ). (Such intertrial differences may reflect blinded vs. open-label study conduct and/or changes in the rate of disease progression that may occur naturally over sufficiently long time scales.) Interpatient variation represented by η 4 was not of any direct interest, but inclusion of this random effect allows for the possibility that changes in slope may not be fully accounted for by changes in exposure.
It was not clear whether the base model with four random effects could be fit reliably to the data, particularly when using a full block covariance matrix (i.e., requiring only that this matrix be positive definite, with no further restrictions). Consequently, random effect covariance matrices with some structural zeroes on the off-diagonal were used. Specifically, the parameters associated with η 4,i were considered to be ancillary, and it was judged to be acceptable to assume that this random effect was uncorrelated with the other three (the other three were, however, allowed to be correlated with each other).
In addition to the linear functions of concentration shown in equations (4) and (5), models with disease progression rates expressed as nonlinear (E max and exponential) functions of concentration were also evaluated.
The base model was extended to incorporate covariate effects as described for the dose-exposure model (see Supporting Information). Covariate effects were formalized as linear adjustments to θ 2 (corresponding to the covariate associations with the natural progression) and/ or θ 3 (corresponding to associations with the effect of exposure).
Model evaluation/simulation and resampling
The adequacy of the final dose-exposure and exposureresponse models was investigated with simple predictive checks and bootstrap predictive check methods. Bootstrap replication and population simulations based on fitted models were used to evaluate the likely effect of higher dose levels as well the effect on enrolling particular baseline characteristics. In total four simulations were performed as follows: (i) bootstrapping of predicted decline rate for a reference individual; (ii) bootstrapping of predicted covariate effects in the exposure-response relationship to evaluate model-predicted differences as functions of covariate settings; (iii) bootstrapping of model-predicted differences in clinical response as a function of covariate settings in the combined dose-exposure-response relationship; and (iv) bootstrapping to predict the likely range of clinical responses if a similar patient population were dosed at 90 or 120 mg kg
Further details of each simulation are provided in the Supporting Information.
weight (kg) and (ii) baseline A 1 -PI. The final dose-exposure model, incorporating these covariate effects, is described below:
Parameter estimates for the final model are provided in Table 2 . Of particular interest is the baseline weight effect on slope (θ 3 = -0.85), which is consistent with allometric scaling of clearance according to Kleiber's law. The exponent is also sufficiently close to -1 to justify weight-based dosing.
The dose-exposure model was used to predict A 1 -PI concentrations as a function of covariate settings. Bootstrap estimates of covariate effects (baseline weight and A 1 -PI) on the dose-exposure model are displayed in Figure 1 and companion of treated patients ( Figure 2A ). Two control patients had postbaseline exposure levels above the protective threshold; these patients were found to be heterozygous for the severe deficiency (Z) allele. Bootstrap population simulations were used to predict the expected range of trough exposure levels at doses of up to 120 mg kg -1 week -1 ( Figure 2B and companion Table S2 ). Of particular note is that the 10 th population percentile at 60 mg kg -1 week -1 is estimated at 12.8 μmol l -1 , which is in line with the observed data shown in Figure 2A .
Exposure-response model
Graphical exploration of individual response trajectories supported the model's piecewise linearity assumption with respect to time (see trajectories for 16 randomly selected individuals in Figure S1 ). Linearity of progression rate with respect to A 1 -PI exposure was also supported over the available range of exposures, in the sense that slopes from separately fitted individual piecewise linear regressions had relationships with exposure that were essentially indistinguishable from linearity (compare the model-based prediction with the loess fit in Figure 3A) . Similarly, the alternative base models with disease progression rates expressed as nonlinear (E max and exponential) functions of concentration resulted in predictions that were practically indistinguishable from the linear model fit over the range of the observed data (results not shown). Since the nonlinear model fits suffered from very large standard errors for the nonlinearity parameters, while providing no predictive advantage, these models were not pursued further.
The final covariates selected were: (i) baseline lung density and (ii) baseline FEV1. The base model was expanded with covariate effect resulting in a final model with FEV1 as a covariate on the rate of natural progression in lung density decline. Thus, the final model may be expressed as:
Parameter estimates for the fitted final exposure-response model can be seen in Table 3 . With the exception of the ω 4 parameter, standard errors and confidence intervals were suggestive of identifiable and well-estimated parameters. Notwithstanding the poor estimation of ω 4 , the η 4 random effects were retained in the model in order to err on the side of more conservative predictive inferences. (Specifically, a model without the η 4 random effects would predict progression rate changes with a nominal degree of precision that would be unwarranted given that there is at least some unexplained interpatient variability in the observed changes.) Diagnostic plots for the final model are available in the Supporting Information (Figures S2 and S3) . The observed slope differences for A 1 -PI vs. placebo revealed a trend toward increasing improvement in lung density decline rate with higher postbaseline A 1 -PI exposure ( Figure 3A) . The model-predicted decline rates as a function of postbaseline exposure ( Figure 3B) show a similar pattern to the observed data; note the differences between the 10 th , 50 th and 90 th percentiles for A 1 -PI vs. placebo (also shown in Table S3 ), demonstrating treatment-effect with A 1 -PI. A similar pattern was also seen when observed slope differences were computed in relation to changes in postbaseline A 1 -PI concentration ( Figure 4A) . Again, the model predicted an analogous relationship to the observed data ( Figure 4B ).
Effect of covariates on exposure-response model
The exposure-response model was used to predict lung density decline rates as a function of covariate settings. The Predicted slopes, as a function of covariates used in both the dose-exposure model and the exposure-response models, are presented in Figure 5 and companion Table S4 . Overall, baseline FEV1 was predicted to have the greatest impact on 
Exposure-response -clinical outcomes
The exposure-response model predicted the median decline rate as -1.56 g l -1 year -1 in A 1 -PI treated patients, compared to -2.17 g l -1 year -1 in placebo. To determine the clinical efficacy of A 1 -PI treatment, the proportion of patients showing improvements in lung density decline rates was determined by simulating from the exposure-response model over a range of thresholds ( Figure 6 ). Over 4 years, an estimated 63% of A 1 -PI-treated patients demonstrated a reduction in annual lung density decline rate (in a positive direction) of 0.50 g l -1 year -1 , compared to 12% of placebo-treated patients. Moreover, Figure 6 demonstrates an increasing separation between A 1 -PI-treated patients and placebotreated patients with higher threshold improvements in lung density decline rate, which further supports treatment effect with A 1 -PI vs. placebo. The stability of the previously described threshold improvements in lung density decline rate (Figure 6 ), were also tested in relation to the covariates examined in both the doseexposure and exposure-response models. Baseline weight, A 1 -PI and FEV1 had negligible effects on the proportion of patients improving by at least 0.50 g l -1 year -1 compared to the previously described reference individual (Table S5) .
Discussion
The present pharmacometric analysis was undertaken to fully explore data from the largest clinical trials of A 1 -PI therapy completed to date, specifically to model the relationships between A 1 -PI dose and exposure, and between A 1 -PI exposure and clinical response. Data from this study confirm weight-based dosing as the most appropriate strategy. Data from the dose-exposure model shows that weight based dosing is able to raise serum A 1 -PI levels above the putative protective threshold in the majority of patients. Additionally, this study is the first to relate A 1 -PI exposure to a clinical endpoint in a pharmacometric analysis. Data from the exposureresponse model support previous findings that treatment with A 1 -PI effectively reduces annual lung density decline in patients with AATD.
Evaluating A 1 -PI dosing strategy
The findings of the dose-exposure analysis strongly support weight-based dosing with A 1 -PI therapy. Our analysis has shown that the current dosing strategy of 60 mg kg -1 week -1 elevates serum levels above the protective threshold in the majority of patients. The close relationship between A 1 -PI and weight is visible in the final parameters for the doseexposure model, with the parameter θ 3 (baseline weight effect on slope) found to be -0.84, which is approximate to -1. A value of exactly -1 would imply an entirely flat relationship between concentration and weight when subjects are dosed proportionally to their weight, as per Kleiber's Law, which observes that metabolic rate scales three-quarters of body mass. These findings are consistent with previous studies that demonstrated the pharmacokinetic efficacy of various A 1 -PI preparations [11] [12] [13] [14] . Moreover, our findings are consistent with a previous population pharmacokinetic analysis of patients in RAPID-RCT, which found average trough levels of 16.2 μmol l -1 with 60 mg kg -1 week -1 A 1 -PI treatment -well above the extrapolated 11 μmol l -1 threshold [13] . The doseexposure model further confirms these findings as ≥98% of A 1 -PI-treated patients attained steady-state serum levels of ≥11 μmol l -1 and the model clearly shows a significant increase in A 1 -PI levels above the historic threshold with active A 1 -PI treatment compared to placebo. Furthermore, the dose-exposure analysis provides limited rationale for dosing strategies that would depend on other covariates. To evaluate possible population variability, covariate influences on the dose-exposure model were examined. Due to the small effect that variability in weight was predicted to have on levels, proportional weight-based dosing with A 1 -PI was determined to be the most appropriate dosing strategy. The model-predicted exposure levels associated with the 10 th and 90 th percentiles for weight in the study population were 15.3 and 16.2 μmol l -1 , respectively. The relatively small difference in these predictions indicates that exposure targets will be met relatively consistently across a range of weights. After weight, the only other covariate in the final dose-exposure model is baseline A 1 -PI exposure. The predictions provided for high and low baseline A 1 -PI values suggest that any effect due to this variable is modest in magnitude. Therefore, weight alone was found to have a significant effect on post-baseline A 1 -PI levels. However, this conclusion is accompanied by a degree of caution since some potential covariate relationships were excluded on the basis of AIC (see Supporting Information).
The dose-exposure model also allowed the extrapolation of exposure levels at higher doses. The model suggests a linear relationship between A 1 -PI dose and exposure, with no clear evidence of a plateau at any serum concentration, including 11 μmol l -1 . Double (120 mg kg -1 ) weekly doses of A 1 -PI have previously been shown to be well tolerated and can increase serum levels further than the standard 60 mg kg -1 dose [11] . Furthermore, in RAPID-RCT, 333 doses of 120 mg kg -1 A 1 -PI were administered to cover 2-week periods, with no relevant increase in treatment-related adverse events observed [15] . However, the long-term safety and efficacy of A 1 -PI therapy at 120 mg kg -1 and above has yet to be proven; data are awaited from studies incorporating 120 mg kg -1 dosing [16, 17] .
Clinical efficacy of A 1 -PI therapy
In contrast to previous pharmacokinetic studies in AATD, the availability of lung density data from the RAPID programme enabled the modelling of A 1 -PI exposure in relation to a valid, clinically-relevant endpoint. The exposure-response model strongly supports the clinical efficacy of 60 mg kg -1 week
A 1 -PI therapy established in RAPID-RCT [6] . Furthermore, predictions for the median decline rate in A 1 -PI vs. placebo patients presented in this analysis are consistent with the 
Figure 6
Proportion of patients exceeding (in the beneficial direction) a threshold abatement in rate of decline, over a range of threshold values. As shown in Table S5 , these estimated proportions do not appreciably depend on covariate settings, and so are shown here under reference (baseline median) covariate settings only. The grey areas indicate the 90% confidence intervals for the true proportion of patients exceeding the threshold (these intervals reflect parameter uncertainty but not interpatient variability, as they refer only to a reference patient)
observed decline rates reported from RAPID-RCT [6] . However, since a high proportion of the variability in observed decline rates is unexplained by the model, substantial regression to the mean occurs, resulting in notable differences between the observed and predicted decline rates. Overall, reductions in lung density decline rates were maintained over the 4-year combined duration of the trials in the Early-Start group, and were comparable between the Early-Start and Delayed-Start groups in RAPID-OLE, where both groups were administered active treatment with weight-based dosing of A 1 -PI. These data support the observed findings from the RAPID programme and the increasing body of evidence that supports the efficacy of A 1 -PI therapy to slow disease progression in patients with AATD [18] [19] [20] . The observed data also suggest a relationship between decreasing lung density decline rates with increasing A 1 -PI exposure and is supported by the analogous model-predicted exposure-response relationship. Specifically, for an increment of 18.5 μmol l -1 in A 1 -PI exposure above A 1 -PI levels associated with placebo, the predicted rate of decline is approximately half of the rate of decline for placebo: 1.11 vs.
, respectively (calculated from data in Table S5 ). Furthermore, by examining individual yearly threshold reductions in lung density decline rate, it is apparent that there is increasing separation between A 1 -PI-treated patients and placebo-treated patients in the proportions of patients achieving more stringent thresholds of clinical improvement (the rate of lung density decline; Figure 6 ). In context, improvements of approximately a quarter of the natural decline rate in the study cohort (0.50 g l -1 year -1 ), occurred regularly in A 1 -PI-treated patients but rarely in placebo-treated patients. The benefit of treatment vs. nontreatment becomes apparent when it is considered that AATD causes irreversible destruction of lung tissue, as demonstrated by the disease-modifying effect of treatment indicated by RAPID-OLE [7] . Evidence is also beginning to show an association between CT lung density and survival, which supports the potential clinical significance of reductions in decline rate such as 0.50 g l -1 year -1 [21] .
Whilst a differential response is not expected as a function of FEV1, patients with lower FEV1 were predicted to have higher lung density decline rates (independent of exposure). This finding is supported by the fact that lung density decline rate, as measured by CT, has previously been correlated with FEV1 [7, 19, 21, 22] . Because lung function once lost is not regained, earlier intervention could potentially be targeted at slowing disease progression and preserving both lung tissue and function.
Model validity and limitations
Overall, there was good correlation between the observed and the predicted data, as indicated by the standard graphical diagnostics we have presented. A number of factors are supportive of the robustness of the models. The models contain only one exceptionally large standard error, namely that for ω 4 . Additionally, refitting the models across bootstrap estimates proved to be successful and when the models were refitted excluding certain data, model-predicted estimates proved to be relatively insensitive. Therefore, these factors suggest that the model parameters are identifiable, stably estimated and are not overly influenced by any outlying points in the data.
The linearity of the dose-exposure relationship is not directly evaluable from the present data as only one dose strength (60 mg kg -1 week -1 ) was administered in the RAPID programme. However, the linearity was previously established in a pharmacokinetic study (RPR 118635-101), which evaluated post-baseline A 1 -PI concentrations at several dose levels [23] . Therefore, a linear relationship between dose and exposure (with no clear evidence of a plateau at any serum concentration) is expected. The safety of higher doses, however, is not evaluable from the present analysis and, as previously discussed, the long-term evidence for the safety of higher A 1 -PI doses, although supportive, remains limited [12, 15, 18, 24, 25] .
The exposure-response model was also fitted in a linear fashion -implying increasing response with increasing exposure. The assumed linearity in the exposure-response relationship is supported over the range of the observed data in the sense that both the nonlinear models and nonparametric fit provided essentially linear predictions over this range. However, it is unlikely that linear extrapolation is valid for extremely high dose levels as this would imply increasing lung densities over time. This would not be possible as the progressive loss of lung tissue is considered to be an irreversible process. Therefore, with the available data, we are not able to estimate at what point the linearity of the relationship between exposure and response ceases to be valid, which limits the utility of the model in predicting response at higher exposure levels. If one were to attempt to identify the plateau in clinical efficacy as A 1 -PI exposure increases, data from a dose-ranging trial -studying higher doses than previously testedwould be required. The inclusion of only a single dose of A 1 -PI in the RAPID programme limited our modelling analysis, and our conclusions must therefore be treated with a degree of caution. However, based on the available data, it remains a valid assumption that higher exposure levels would plausibly yield greater reductions in lung density decline rates. Although biomarker data might have informed construction of a mechanistic pharmacokinetic/ pharmacodynamic model, no validated biomarker currently exists to assess disease progression in A 1 -PI deficiency. Therefore, the model presented is empirical in nature.
Moreover, there are also limitations surrounding the finding that the final dose-exposure-response model shows extremely uniform outcomes across the covariate settings tested. This is a tentative finding, as potential covariate relationships were excluded on the basis of AIC (see Supporting Information). Nonetheless, the assumption that efficacy as reflected by slope change does not depend on the measured covariates remains a valid working assumption based on the available data.
Conclusions
Our analysis is highly supportive of weight-based dosing as a stable, predictable method of A 1 -PI administration. Moreover, the current 60 mg kg -1 week -1 dosing strategy achieves adequate A 1 -PI levels above the 11 μmol l -1 protective threshold in >98% of patients studied. We found no clear evidence of a plateau in clinical efficacy as A 1 -PI exposure increased, calling into question whether 11 μmol l -1 is the maximal, clinically effective threshold for A 1 -PI therapy in AATD. The exposure-response model supports the conclusion from the primary RAPID-RCT analysis that A 1 -PI therapy is clinically effective in slowing the rate of lung density decline in patients with AATD. Improvements in decline rate of at least 0.50 g l -1 year -1 (approximately a quarter or the natural decline rate) occurred more frequently in A 1 -PI-treated patients vs. placebo. Final dose-exposure-response simulations indicated the limited effect that covariates had on slope change with A 1 -PI. Low FEV1 was determined to be a predictor of lower lung density, providing a rationale to potentially treat those patients earlier in an effort to slow disease progression and delay the eventual loss of lung tissue and function.
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